Interviews - Operator: Thank you for holding. Welcome to the Selecta Biosciences fourth quarter and year end 2017 conference call. Currently all participants are in a listen … Continue Reading
Read NowInterviews - A recent FDA bulletin puts the success rate of Phase II clinical trials at just 18%, 50% in Phase III, citing insufficient efficacy and safety concerns as the … Continue Reading
Read NowInterviews - Sarepta Therapeutics (SRPT) had a tumultous year, reaching an all-time high of $55.00 last October before tumbling to lows under $13.00 when the U.S. FDA suggested that the company would need to … Continue Reading
Read NowInterviews - Shares of Trius Therapeutics (TSRX) took a 7% dive on Wednesday, creating an entrance opportunity for those not yet involved, as the unsubstantiated rumors that … Continue Reading
Read NowInterviews - On April 11, PropThink hosted an Interview and Q&A (via conference call) for PropThink subscribers with Dr. Scott Chambers, a leading patent attorney and former … Continue Reading
Read NowInterviews - The CPAP (Continuous Positive Airway Pressure) equipment market is about to enter a pivotal time. The Centers for Medicare and Medicaid (CMS) instituted a round … Continue Reading
Read NowInterviews - In an exclusive PropThink interview with ARIAD Pharmaceuticals (NASDAQ:ARIA), CEO Harvey J. Berger discusses the company’s lead product, ponatinib, a potential treatment for intolerant Chronic … Continue Reading
Read Now
